Evidence map›Paper›PMID 21748298›Full record

ArticleInvestigational new drugs2012

Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo.

Juan R Rodrigues, Jaime Charris, Rosa Ferrer, Neira Gamboa, Jorge Angel, Bianca Nitzsche, Michael Hoepfner, Michael Lein, Klaus Jung, Claudia Abramjuk

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. One-Pot Multicomponent Synthesis of Methoxybenzo[Molecules (Basel, Switzerland) · 2021
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Juan R RodriguesDepartment of Urology, University Hospital Charité, Campus Charité Mitte, Schumannstrasse 20/21, 10117 Berlin, Germany.
Jaime Charris
Rosa Ferrer
Neira Gamboa
Jorge Angel
Bianca Nitzsche
Michael Hoepfner
Michael Lein
Klaus Jung
Claudia Abramjuk
Central University of Venezuela · VECharité - Universitätsmedizin Berlin · DEEcologic Institute · DEUniversity of Zulia · VE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quinolines and acrylates are chemical compounds which were previously described as potential antitumor agents. In this study, a series of seven new quinolinyl acrylate derivatives were synthesized and evaluated against human prostate cancer cells PC-3 and LNCaP in vitro and in vivo. The most effective compound (E)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4 hydroxyphenyl) acrylate reduced the viability in both cell lines in a time- and dose-dependent manner. Inhibitory effects were also observed on the adhesion, migration, and invasion of the prostate cancer cells as well as on the neoangiogenesis, clonogenic and MMP-9 activity. The effect in vivo was studied in PC-3 xenografts in nude mice. The results were concordant with the in vitro effects and showed decreased tumor growth in treated animals compared to controls. The study suggests the multi-target efficacy of the quinolinyl derivate against human prostate cancer cells and supports its potential therapeutic usefulness.

Indexed as

AcrylatesAngiogenesis InhibitorsAnimalsAntineoplastic AgentsCell AdhesionCell DeathCell MovementCell ProliferationCell SurvivalChickensClone CellsDose-Response Relationship, DrugHumansInhibitory Concentration 50MaleMatrix Metalloproteinase 9AcrylatesAngiogenesis InhibitorsAntineoplastic AgentsMatrix Metalloproteinase 9Quinolines

Identifiers

PMID21748298
OpenAlexW2015014882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.